BioPharma Resources

Investigational drug · Phase 2

brivekimig

Also called: SAR442970

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

5

5 still active

All registered trials

5

Any phase or sponsor naming "brivekimig"

First trial start

2024

Dec 19, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "brivekimig", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Focal Segmental Glomerulosclerosis
  • Glomerulonephritis Minimal Lesion
  • Type 1 Diabetes Mellitus
  • Crohn's Disease
  • Ulcerative Colitis
  • Hidradenitis Suppurativa

Approved drugs for the same conditions: Type 1 diabetes · Crohn's disease · Ulcerative colitis · Hidradenitis suppurativa · Cardiovascular and metabolic · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "brivekimig" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Focal Segmental Glomerulosclerosis

  • FrexalimabSAR441344Phase 39 trials

    Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

  • BI 764198ApecotrepPhase 33 trials

    Boehringer Ingelheim · Focal Segmental Glomerulosclerosis, Proteinuric Kidney Diseases, Kidney Disease, Chronic

  • R3R01Phase 22 trials

    River 3 Renal Corp. · Diabetic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.